Clinical trials: Pharmacodynamics
Diabetes Mellitus Type 2
A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment
This 4 arm study will investigate the pharmacodynamics and pharmacokinetics of RO4998452 in type 2 diabetes patients with varying degrees of renal impairment.
- Trial name
- NCT00933972
- Testing
- RO4998452
- Where
- 2 sites in United States, Russia
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Malignant Neoplasm
TSN084 Treating Patients With Advanced Malignant Tumors
TSN084 is a novel type II kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19.
- Trial name
- NCT06386705
- Testing
- TSN084
- Where
- 2 sites in China
- Volunteers
- 114 people
- Sponsor
- Tyligand Bioscience (Shanghai) Limited
Hepatitis B
A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects
This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects.
- Trial name
- NCT06160895
- Testing
- TQ-A3334 tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Asthma
Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma
This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma
- Trial name
- NCT01103037
- Testing
- QAV680
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in…
- Trial name
- NCT06421935
- Testing
- M9466, Tuvusertib, Abiraterone acetate
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Psoriasis
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to severe psoriasis.
- Trial name
- NCT01577550
- Testing
- BI 655066 (very high i.v. dose), BI 655066 (high s.c. dose), BI 655066 (low i.v. dose)
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 39 people
- Sponsor
- AbbVie
Relapsed/Refractory B-cell Malignancies
This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies
This is a Phase 1 study of MH048 in patients with selected Relapsed/Refractory B-cell Malignancies.
- Trial name
- NCT04689308
- Testing
- MH048
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Minghui Pharmaceutical (Shanghai) LTD
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Refractory Hematologic Cancer
A Study of BMS-863233 in Patients With Hematologic Cancer
To determine safety, tolerability and maximum tolerated dose of BMS-63233/XL413 in subjects with Refractory Hematologic Cancer
- Trial name
- NCT00838890
- Testing
- Cdc7-inhibitor (BMS-863233)
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects
This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.
- Trial name
- NCT03830125
- Testing
- BBT-877, Single dose, BBT-877, Multiple doses
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Bridge Biotherapeutics, Inc.
Cervical Cancer
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
The goal of this clinical trial is to learn if the therapy of JSKN033 plus chemotherapy with or with bevacizumab is safe to treat patients with advanced cervical cancer.
- Trial name
- NCT07497074
- Testing
- JSKN033, Platinum, Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Diabetes Mellitus, Type 2
A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers
The primary purpose of this study is to evaluate pharmacodynamics of single oral doses of PF-05175157 in a dose-dependent fashion in healthy volunteers
- Trial name
- NCT01537497
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rheumatoid Arthritis
Study of an Anti-TLR4 mAb in Rheumatoid Arthritis
This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis
- Trial name
- NCT03241108
- Testing
- NI-0101
- Where
- 19 sites in Bosnia and Herzegovina, Bulgaria and 5 more
- Volunteers
- 90 people
- Sponsor
- Light Chain Bioscience - Novimmune SA
Calciphylaxis
SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease
This Phase 1, open-label, multicenter study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INZ-701 in adults with hemodialysis-dependent end-stage kidney disease (ESKD) and low plasma inorganic…
- Trial name
- SEAPORT 1 (NCT06283589)
- Testing
- INZ-701
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Inozyme Pharma
Dermatomyositis
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered GLPG3667 once daily for 24 weeks in adult participants with dermatomyositis…
- Trial name
- GALARISSO (NCT05695950)
- Testing
- GLPG3667
- Where
- 54 sites in United States, Argentina and 13 more
- Volunteers
- 40 people
- Sponsor
- Lakefront Biotherapeutics NV
Healthy
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects
This Phase 1 study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of ACT-1004-1239 in healthy subjects.
- Trial name
- NCT03869320
- Testing
- ACT-1004-1239, ACT-1004-1239 (Food-effect subpart)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of NNC 0148-0000-0362 as tablets in healthy…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01597713
- Testing
- NNC 0148-0000-0362, insulin glargine
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Psoriasis
Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis
Calcipotriene is a vitamin D3 analog that has been used as topical therapy in adult subjects with plaque-type psoriasis since 1993.
- Trial name
- NCT01563068
- Testing
- Calcipotriene 0.005% Foam
- Where
- 9 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mayne Pharma International Pty Ltd
Macular Degeneration
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00333476
- Testing
- MSI-1256F (Squalamine Lactate)
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Genaera Corporation
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate pharmacokinetics, pharmacodynamics and safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- NCT01697618
- Testing
- biphasic insulin aspart 30, biphasic human insulin 30
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.